The selection of Standard of Care is still one of the hottest controversial topics in upper gastrointestinal tumours. In this ESMO Podcast series, experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.
Controversies in upper GI oncology: First-line checkpoint inhibitor use in metastatic GEA
In this podcast, Dr. Angelica Petrillo interviews Dr. Steven Maron and Dr. Raghav Sundar about the following issue: First-line checkpoint inhibitor use in metastatic gastroesophageal adenocarcinoma (GEA): guided by PD-L1 combined positive score (CPS) or not? The two experts debate about the pros and cons of using PD-L1 CPS to select patients as well as future perspectives.
Published in March 2023
Controversies in upper GI oncology: Neoadjuvant CRT vs neoadjuvant CT in oesophageal adenocarcinoma
In this podcast, Dr Angelica Petrillo interviews Prof Hanneke WM van Laarhoven and Prof Sylvie Lorenzen about the best choice for neoadjuvant treatment for non-metastatic oesophageal adenocarcinoma: chemoradiotherapy or chemotherapy? The two experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.
Published in September 2022